NATCO PHARMA LTD, one of the biggest pharmaceutics in India announced that they have receive a volume-limited license to sell generic Lenalidomide in the United States from March 2022. And get a patent to sell an unlimited quantity of generic Lenalidomide in the United States at the beginning of 2026.
It seems a bomb news in united states. But it is surely not a news in India drug market. In united states, the most popular REVLIMID (lenalidomide) 25mg is 20396USD per 30 tablets. The Natco India generic Lenmid-25 (lenalidomide) is 193USD per 30 Tablets from online pharmacy. Which one to choose if you can? it is not a hard question.
MM, with the name of multiple myeloma, is a serious cancer arising from plasma cells, a type of white blood cell which is made in the bone marrow.
REVLIMID (lenalidomide) is a prescription medicine, used to treat people with: Multiple myeloma (MM); myelodysplastic syndromes (MDS) and Mantle cell lymphoma (MCL).
There are 2 main manufacture of Generic lenalidomide with the name of Lenalid and , which is one of the 2 biggest listed pharmaceutics in India. The following is the items they sale and whole sales price:
Lenalidomide (Revlimid) Indications:
1. Multiple myeloma (MM)
(1) In combination with the medicine dexamethasone, or
(2) As maintenance treatment after autologous hematopoietic stem cell transplantation (a type of stem cell transplant that uses your own stem cells)
2. A condition called myelodysplastic syndromes (MDS). Lenalidomide is for the type of MDS with a chromosome problem where part of chromosome 5 is missing. This type of MDS is known as deletion 5q MDS. People with this type of MDS may have low red blood cell counts that require treatment with blood transfusions.
3. Mantle cell lymphoma (MCL) when the disease comes back or becomes worse after treatment with two prior medicines, one of which included bortezomib. MCL is a cancer of a type of white blood cell called lymphocytes that are in the lymph nodes.
Limitations of Use:
Lenalid (Revlimid) 10mg is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
DOSAGE AND ADMINISTRATION:
1.MM combination therapy: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles. Refer to section 14.1 for dexamethasone dosing.
2. MM maintenance therapy following auto-HSCT: 10 mg once daily continuously on Days 1-28 of repeated 28-day cycles.
3.MDS: 10 mg once daily.
4. MCL: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles.
5.Continue or modify dosing based on clinical and laboratory findings.
6. Renal impairment: Adjust starting dose based on the creatinine clearance value
1.Pregnancy (Boxed Warning)
2.Demonstrated severe hypersensitivity to lenalidomide.
Lenalidomide (Revlimid)Side Effect: (ADVERSE REACTIONS)
1.MM: Most common adverse reactions (≥20%) include diarrhea, fatigue, anemia, constipation, neutropenia, leukopenia, peripheral edema, insomnia, muscle cramp/spasms, abdominal pain, back pain, nausea, asthenia, pyrexia, upper respiratory tract infection, bronchitis, nasopharyngitis, gastroenteritis, cough, rash, dyspnea, dizziness, decreased appetite, thrombocytopenia, and tremor
2.MDS: Most common adverse reactions (>15%) include thrombocytopenia, neutropenia, diarrhea, pruritus, rash, fatigue, constipation, nausea, nasopharyngitis, arthralgia, pyrexia, back pain, peripheral edema, cough, dizziness, headache, muscle cramp, dyspnea, pharyngitis, and epistaxis
3.MCL: Most common adverse reactions (≥15%) include neutropenia, thrombocytopenia, fatigue, diarrhea, anemia, nausea, cough, pyrexia, rash, dyspnea, pruritus, constipation, peripheral edema and leukopenia